Mesenchymal Stem Cells Show Early Promise in Moderate-to-Severe Atopic DermatitisStem cells show potential for treating severe atopic dermatitis

Stem cells and development Published October 1, 2026 Study authors: Cevallos-Cueva Martin, Ghanem Laura, Novis Taissa, Arora Sakshi, Kirmani Najwaa, Aktaş Sümeyye, Fern… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider MSC therapy for atopic dermatitis as early evidence only, limited by small trials.

This meta-analysis examined mesenchymal stem cells (MSCs) from human umbilical cord blood, autologous adipose tissue, and allogeneic bone marrow in patients with moderate-to-severe atopic dermatitis. The pooled sample included 236 patients. The primary outcomes were the proportion achieving at least 50% and at least 75% improvement from baseline in the Eczema Area and Severity Index (EASI).

At week 12, the EASI-50 response rate was 46.76% (95% CI 32.36% to 61.72%) and the EASI-75 response rate was 17.41% (95% CI 5.56% to 43.03%). At week 16, the EASI-75 response rate was 23.97% (95% CI 16.48% to 33.50%). Adverse events were reported in 26.86% (95% CI 19.56% to 35.68%). Serious adverse events, discontinuations, and tolerability were not reported.

The authors note that the evidence is largely based on small clinical trials. Follow-up duration, comparator, and funding or conflicts of interest were not reported. These gaps limit interpretation of the pooled estimates.

MSCs are described as a potential alternative to traditional therapies for moderate-to-severe atopic dermatitis. However, given the small trial base and wide confidence intervals, these findings should be considered early and hypothesis-generating rather than practice-changing.

How this fits prior evidence

This meta-analysis extends prior coverage of mesenchymal stem cells for allergic rhinitis, where functionalized MSCs and exosomes showed potential anti-inflammatory effects. It also follows coverage of dupilumab for severe pediatric atopic dermatitis, though that item concerned a possible temporal association with vitiligo and did not establish causality. The current findings provide pooled response rates for MSCs in atopic dermatitis, a condition not previously addressed by the MSC evidence summarized here. However, the small trial base limits comparison with established therapies.

Living with moderate to severe atopic dermatitis can be exhausting. The constant itching and skin irritation often make it hard to find lasting relief. Researchers are looking into mesenchymal stem cells as a possible new way to treat this condition. These are types of cells found in umbilical cord blood, fat tissue, and bone marrow.

In a review of data from 236 patients, researchers found that stem cell treatments showed some signs of improvement. About 46.76% of patients saw a 50% improvement in their skin condition by week 12. By week 16, about 23.97% of patients saw a 75% improvement. These numbers suggest the treatment might work for some people, but the results vary.

It is important to note that these findings come from small clinical trials. While the treatment was generally tolerated, about 26.86% of patients still experienced some side effects. Because the evidence is still limited, this is not a replacement for standard care yet, but it offers a potential path for those seeking new options.

What this means for you:

Stem cell therapy shows some promise for severe eczema, but more large-scale research is needed.

Common questions

What kind of stem cells were used for this treatment?

The study looked at mesenchymal stem cells. These specific cells were taken from three different sources: human umbilical cord blood, fat tissue (autologous adipose tissue), and bone marrow (allogeneic bone marrow). These cells are being studied as a potential alternative to traditional therapies for moderate to severe atopic dermatitis.

How well did the stem cell treatment work for skin symptoms?

By week 12, 46.76% of patients saw at least a 50% improvement in their skin. By week 16, about 23.97% of patients saw a 75% improvement. Because the evidence comes from small trials, these results are still being evaluated for how well they work for everyone.

Is the stem cell treatment safe for patients?

The study reported that about 26.86% of patients experienced some adverse events. While the treatment is being explored as a potential option, the evidence is currently based on small clinical trials, so you should talk to your doctor about the risks and benefits for your specific case.

Study Details

Study typeMeta analysis

Sample sizen = 236

EvidenceLevel 1

PublishedOct 2026

PMID42596527

View Original Abstract ↓

Despite currently available treatment options for moderate-to-severe atopic dermatitis (AD), some patients fail to achieve adequate disease control. Emerging evidence suggests that mesenchymal stem cells (MSCs) may represent a promising therapeutic option. This systematic review and meta-analysis included four randomized controlled trials (RCTs) and one non-randomized clinical trial. Eligible studies evaluated patients with moderate-to-severe AD treated with MSCs derived from human umbilical cord blood, autologous adipose tissue, and allogeneic bone marrow. PubMed, Embase, and Cochrane were searched from inception to December 2025. Primary outcomes included the proportion of patients achieving ≥50% and ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI) and safety outcomes. The meta-analysis included 236 participants. The pooled EASI-50 response rate at week 12 was 46.76% (95% confidence interval [CI]: 32.36% to 61.72%). EASI-75 response rates were 17.41% (95% CI: 5.56% to 43.03%) at week 12 and 23.97% (95% CI: 16.48% to 33.50%) at week 16. The pooled incidence of treatment-emergent adverse events was 26.86% (95% CI: 19.56% to 35.68%), with infections and infestations 7.97% (95% CI: 4.11% to 14.88%) and gastrointestinal disorders 3.52% (95% CI: 1.33% to 9.01%) being the most frequently reported. MSC-based therapy shows early promise as a potential treatment for moderate-to-severe AD, offering a possible alternative to traditional therapies. However, the current evidence is largely based on small clinical trials, underscoring the necessity for large-scale RCTs to establish the efficacy and safety of MSC-based therapy in broader patient populations.

Mesenchymal Stem Cells Show Early Promise in Moderate-to-Severe Atopic DermatitisStem cells show potential for treating severe atopic dermatitis

How this fits prior evidence

Common questions

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Mesenchymal Stem Cells Show Early Promise in Moderate-to-Severe Atopic DermatitisStem cells show potential for treating severe atopic dermatitis

How this fits prior evidence

Common questions

More on Atopic Dermatitis

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties